

Paolo Martelletti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5533259/paolo-martelletti-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

258
papers

6,043
citations

41
h-index

62
g-index

316
ext. papers

7,791
ext. citations

5.9
avg, IF

6.55
L-index

#	Paper	IF	Citations
258	Access to COVID-19 Vaccination during the Pandemic in the Informal Settlements of Rome.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	1
257	Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes.. <i>Expert Review of Neurotherapeutics</i> , 2022 , 1-7	4.3	2
256	Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity.. <i>Pain and Therapy</i> , 2022 , 1	3.6	0
255	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.. <i>Journal of Headache and Pain</i> , 2022 , 23, 41	8.8	4
254	Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	4
253	The Global Campaign turns 18: a brief review of its activities and achievements.. <i>Journal of Headache and Pain</i> , 2022 , 23, 49	8.8	3
252	Zavegepant. <i>Headache</i> , 2022 , 67-72	0.2	
251	Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine.. <i>BioDrugs</i> , 2022 , 1	7.9	2
250	Hormonal therapies in migraine management: current perspectives on patient selection and risk management. <i>Expert Review of Neurotherapeutics</i> , 2021 , 1-9	4.3	1
249	Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. <i>Pain and Therapy</i> , 2021 , 10, 1691-1708	3.6	2
248	CHA2DS2-VASc score in patients with COVID-19 pneumonia and its relationship with biomarkers of thrombosis, inflammation and myocardial injury. <i>Blood Coagulation and Fibrinolysis</i> , 2021 ,	1	1
247	Novel synthetic treatment options for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 907-922	4	9
246	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , 2021 , 10, 637-650	3.6	4
245	CGRP Receptor Antagonists and 5-HT _{1F} Receptor Agonist in the Treatment of Migraine. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	8
244	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021 , 16, 1005-1015	3.7	16
243	Medication overuse and drug addiction: a narrative review from addiction perspective. <i>Journal of Headache and Pain</i> , 2021 , 22, 32	8.8	4
242	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. <i>Journal of Headache and Pain</i> , 2021 , 22, 39	8.8	8

241	Long-COVID Headache. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 3, 1-3	2.7	13
240	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021 , 17, 501-514	15	33
239	Eptinezumab for the treatment of migraine. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 999-1011	5.4	2
238	Cluster Headache is Still Lurking in the Shadows. <i>Pain and Therapy</i> , 2021 , 10, 777-781	3.6	2
237	Recent advancements in tension-type headache: a narrative review. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 793-803	4.3	4
236	Comorbidities of primary headache disorders: a literature review with meta-analysis. <i>Journal of Headache and Pain</i> , 2021 , 22, 71	8.8	15
235	New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. <i>Journal of Medical Virology</i> , 2021 , 93, 97-98	19.7	45
234	Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection. <i>American Journal of Infection Control</i> , 2021 , 49, 640-642	3.8	36
233	Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. <i>Pain and Therapy</i> , 2021 , 10, 1-13	3.6	9
232	Recurrent COVID-19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?. <i>Journal of Medical Virology</i> , 2021 , 93, 1882-1884	19.7	19
231	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 249-254	4.3	1
230	Evaluating and managing severe headache in the emergency department. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 277-285	4.3	9
229	Healthcare resource use and indirect costs associated with migraine in Italy: results from the survey. <i>Journal of Medical Economics</i> , 2021 , 24, 717-726	2.4	4
228	Fremanezumab. <i>Headache</i> , 2021 , 131-136	0.2	1
227	Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	26
226	Migraine Versus Cluster Headache and Potential Other Indications. <i>Headache</i> , 2021 , 167-172	0.2	
225	Right Heart Thrombus and Pulmonary Embolism in Patients with Life-Threatening Bleeding: Management of a Complex Condition. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 3, 793-795	2.7	
224	Structural and Functional Brain Changes in Migraine. <i>Pain and Therapy</i> , 2021 , 10, 211-223	3.6	11

223	Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	9
222	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , 2021 , 22, 832-839	1.9	3
221	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , 2021 , 10, 1605-1618	3.6	0
220	Zavegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. <i>Drugs of the Future</i> , 2021 , 46, 281	2.3	3
219	Etiology of 'Sinus Headache'-Moving the Focus from Rhinology to Neurology. A Systematic Review. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
218	New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient 2021 , 93, 97		1
217	How Does COVID-19 Pandemic Impact on Incidence of Infection and Exacerbation of Its Gastrointestinal Symptoms?. <i>Frontiers in Medicine</i> , 2021 , 8, 775063	4.9	1
216	Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN.. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 4, 3	2.7	0
215	Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-2	2.7	8
214	Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre. <i>Journal of Headache and Pain</i> , 2020 , 21, 44	8.8	8
213	European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). <i>Journal of Headache and Pain</i> , 2020 , 21, 76	8.8	47
212	Rapid referral for headache management from emergency department to headache centre: four years data. <i>Journal of Headache and Pain</i> , 2020 , 21, 25	8.8	10
211	Flail Mitral Valve Associated with Iliac Artery Aneurysm: Diagnostic Challenges of a Potential Syndromic Pattern. Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 481-484	2.7	
210	The Relation between Persistent Post-Traumatic Headache and PTSD: Similarities and Possible Differences. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	9
209	Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization. <i>Journal of Headache and Pain</i> , 2020 , 21, 86	8.8	12
208	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-6	2.7	25
207	New Model for Non-Invasive Echocardiographic Assessment of Pulmonary-Capillary Wedge Pressure in Patients With Aortic and Mitral Regurgitation. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 914-918	2.7	1
206	Ubrogepant for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 755-759	4	16

205	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 313-317	4.3	13
204	Gut-brain Axis and migraine headache: a comprehensive review. <i>Journal of Headache and Pain</i> , 2020 , 21, 15	8.8	80
203	Using INTERCheck to Evaluate the Incidence of Adverse Events and Drug-Drug Interactions in Out- and Inpatients Exposed to Polypharmacy. <i>Drugs - Real World Outcomes</i> , 2020 , 7, 243-249	2.2	4
202	"Triaging" Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies. <i>Pain and Therapy</i> , 2020 , 9, 349-351	3.6	
201	Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	16
200	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <i>Journal of Headache and Pain</i> , 2020 , 21, 55	8.8	18
199	Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine. <i>Drugs of the Future</i> , 2020 , 45, 285	2.3	8
198	Rimegepant for the treatment of migraine. <i>Drugs of Today</i> , 2020 , 56, 769-780	2.5	1
197	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	6
196	Global Burden of Headache Disorders in Children and Adolescents 2007-2017. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	13
195	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. <i>F1000Research</i> , 2020 , 9, 1470	3.6	2
194	Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 627-641	4.3	27
193	Acute headache management in emergency department. A narrative review. <i>Internal and Emergency Medicine</i> , 2020 , 15, 109-117	3.7	15
192	The clinical and public health implications and risks of widening the definition of chronic migraine. <i>Cephalalgia</i> , 2020 , 40, 407-410	6.1	7
191	Profiling lasmiditan as a treatment option for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 147-153	4	15
190	Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4	2.7	15
189	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1467-1476	3.7	28
188	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 1275-1286	4.3	5

187	Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. <i>Journal of Headache and Pain</i> , 2020 , 21, 90	8.8	4
186	Extremely Severe Case of COVID-19 Pneumonia Recovered Despite Bad Prognostic Indicators: a Didactic Report. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4	2.7	20
185	COVID-19: is it just a lung disease? A case-based review. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-6	2.7	28
184	Migraine and sleep disorders: a systematic review. <i>Journal of Headache and Pain</i> , 2020 , 21, 126	8.8	24
183	Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	2
182	Prophylactic Drugs. <i>Headache</i> , 2020 , 135-151	0.2	
181	Air Pollution and the Novel Covid-19 Disease: a Putative Disease Risk Factor. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-5	2.7	126
180	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. <i>F1000Research</i> , 2020 , 9, 1470	3.6	2
179	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. <i>Journal of Headache and Pain</i> , 2019 , 20, 92	8.8	65
178	Job Satisfaction Mediates the Association between Perceived Disability and Work Productivity in Migraine Headache Patients. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	7
177	Fremanezumab for the preventive treatment of migraine in adults. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 741-748	3.8	12
176	Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). <i>Journal of Headache and Pain</i> , 2019 , 20, 60	8.8	15
175	Migraine and cluster headache show impaired neurosteroids patterns. <i>Journal of Headache and Pain</i> , 2019 , 20, 61	8.8	11
174	Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 769-776	4.3	17
173	Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. <i>Journal of Headache and Pain</i> , 2019 , 20, 57	8.8	98
172	Optimising migraine treatment: from drug-drug interactions to personalized medicine. <i>Journal of Headache and Pain</i> , 2019 , 20, 56	8.8	27
171	Gepants for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 555-567	5.9	62
170	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. <i>Journal of Headache and Pain</i> , 2019 , 20, 26	8.8	38

169	CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. <i>Journal of Headache and Pain</i> , 2019 , 20, 27	8.8	47
168	Unmet Needs in Headache Management. <i>Headache</i> , 2019 , 13-25	0.2	1
167	Erenumab is effective in reducing migraine frequency and improving physical functioning. <i>BMJ Evidence-Based Medicine</i> , 2019 , 24, 76	2.7	11
166	Cytomegalovirus Reactivation in Critically Ill Patient: Cause or Consequence? A Case Report and Literature Review. <i>SN Comprehensive Clinical Medicine</i> , 2019 , 1, 633-636	2.7	
165	The future of pharmacogenetics in the treatment of migraine. <i>Pharmacogenomics</i> , 2019 , 20, 1159-1173	2.6	5
164	Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. <i>Drugs of the Future</i> , 2019 , 44, 635	2.3	4
163	Fremanezumab for the prevention of chronic and episodic migraine. <i>Drugs of Today</i> , 2019 , 55, 265-276	2.5	7
162	Dismantling the Barriers. <i>Headache</i> , 2019 , 185-201	0.2	1
161	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. <i>Journal of Headache and Pain</i> , 2019 , 20, 15	8.8	4
160	Association of diet and headache. <i>Journal of Headache and Pain</i> , 2019 , 20, 106	8.8	41
159	Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. <i>Journal of Headache and Pain</i> , 2019 , 20, 120	8.8	28
158	Advances in orally administered pharmacotherapy for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 209-218	4	14
157	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , 2019 , 20, 6	8.8	158
156	Illness Perception and Job Satisfaction in Patients Suffering from Migraine Headaches: Trait Anxiety and Depressive Symptoms as Potential Mediators. <i>Headache</i> , 2019 , 59, 46-55	4.2	3
155	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 167-176	4.3	18
154	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. <i>Pain</i> , 2018 , 159, 673-683	8	50
153	Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. <i>Journal of Pain Research</i> , 2018 , 11, 515-526	2.9	51
152	Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. <i>Journal of Headache and Pain</i> , 2018 , 19, 68	8.8	11

151	Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	1
150	Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. <i>Neurology</i> , 2018 , 91, e364-e373	6.5	130
149	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2018 , 9,	4.1	78
148	My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. <i>Journal of Headache and Pain</i> , 2018 , 19, 115	8.8	76
147	Emerging drugs for migraine treatment: an update. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 301-318	3.7	34
146	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2018 , 19, 91	8.8	64
145	Pharmacogenetic considerations for migraine therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1161-1167	5.5	9
144	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , 2018 , 19, 101	8.8	23
143	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , 2018 , 19, 98	8.8	12
142	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , 2018 , 19, 76	8.8	34
141	Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine. <i>CNS Drugs</i> , 2018 , 32, 559-565	6.7	8
140	Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache. <i>Pain Practice</i> , 2017 , 17, 392-401	3	23
139	Lasmiditan for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 227-234	5.9	29
138	Acute treatment of migraine: quo vadis?. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1035-1037	4	5
137	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). <i>Journal of Headache and Pain</i> , 2017 , 18, 108	8.8	91
136	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. <i>Journal of Headache and Pain</i> , 2017 , 18, 93	8.8	13
135	Cognition, disability and quality of life of patients with chronic migraine. <i>European Psychiatry</i> , 2017 , 41, s501-s501	6	1
134	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017 , 19, 32	4.4	13

133	The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. <i>BioDrugs</i> , 2017 , 31, 483-485	7.9	17
132	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , 2017 , 18, 66	8.8	23
131	Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. <i>Journal of Pain Research</i> , 2017 , 10, 2751-2760	2.9	33
130	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2017 , 8, 586	4.1	33
129	Headache: Cluster headache treatment - RCTs versus real-world evidence. <i>Nature Reviews Neurology</i> , 2016 , 12, 557-8	15	12
128	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 1217-27	4.3	20
127	Anti-CGRP monoclonal antibodies in migraine: current perspectives. <i>Internal and Emergency Medicine</i> , 2016 , 11, 1045-1057	3.7	37
126	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 414-23	6.6	15
125	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 399-406	5.5	27
124	General Principles of Pharmacotherapy for Headache Disorders. <i>Headache</i> , 2016 , 19-29	0.2	
123	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1011-20	5.5	5
122	Headache service quality: evaluation of quality indicators in 14 specialist-care centres. <i>Journal of Headache and Pain</i> , 2016 , 17, 111	8.8	19
121	Depression and insomnia are independently associated with satisfaction and enjoyment of life in medication-overuse headache patients. <i>International Journal of Psychiatry in Medicine</i> , 2016 , 51, 442-455 ¹		6
120	EV435 Life satisfaction and enjoyment in medication-overuse headache patients: The role of depression and insomnia. <i>European Psychiatry</i> , 2016 , 33, S395-S395	6	1
119	Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: A prospective, open-label, exploratory study. <i>European Journal of Pain</i> , 2016 , 20, 70-8	3.7	38
118	Correlation between Migraine Severity and Cholesterol Levels. <i>Pain Practice</i> , 2015 , 15, 662-70	3	24
117	Questioning on consistency of a stagnation scale in medication overuse headache: one more added to a plea of emperor's clothes?. <i>Journal of Headache and Pain</i> , 2015 , 16, 13	8.8	2
116	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015 , 10, 413-21	3.7	17

115	Update on Medication-Overuse Headache and Its Treatment. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 368	4.4	11
114	Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 215-25	4.3	7
113	Chronic Migraine Complicated by Medication Overuse Headache. <i>Headache</i> , 2015 , 29-34	0.2	
112	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. <i>Journal of Headache and Pain</i> , 2015 , 17, 27	8.8	32
111	Altered kynurenine pathway metabolites in serum of chronic migraine patients. <i>Journal of Headache and Pain</i> , 2015 , 17, 47	8.8	39
110	European Headache Federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015 , 17, 5	8.8	66
109	Psychometric properties of the stagnation scale in medication overuse headache patients. <i>Journal of Headache and Pain</i> , 2015 , 16, 1052	8.8	15
108	Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Headache and Pain</i> , 2015 , 16, A36	8.8	1
107	P067. Multimodal therapy in the management of MOH: a 3-year experience. <i>Journal of Headache and Pain</i> , 2015 , 16, A135	8.8	2
106	P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. <i>Journal of Headache and Pain</i> , 2015 , 16, A137	8.8	3
105	P003. NSAIDs for symptomatic treatment of headache. <i>Journal of Headache and Pain</i> , 2015 , 16, A162	8.8	1
104	O068. A 2 years prospective evaluation study on onabotulinumtoxinA 195 U in chronic migraine. <i>Journal of Headache and Pain</i> , 2015 , 16, A177	8.8	1
103	P064. 12 years of Master Degree in Headache Medicine at Sapienza University of Rome. <i>Journal of Headache and Pain</i> , 2015 , 16, A187	8.8	2
102	Invasive neurostimulation. <i>Journal of Headache and Pain</i> , 2015 , 16, A29	8.8	
101	O066. Kynurenine pathway metabolites in cluster headache. <i>Journal of Headache and Pain</i> , 2015 , 16, A87	8.8	0
100	O065. Drug-resistant chronic cluster headache successfully treated with supraorbital plus occipital nerve stimulation. A rare case report. <i>Journal of Headache and Pain</i> , 2015 , 16, A97	8.8	2
99	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. <i>Journal of Headache and Pain</i> , 2015 , 17, 1	8.8	93
98	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , 2015 , 4, 826		50

97	Emerging drugs for migraine treatment. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 137-47	3.7	31
96	Refractory Chronic Migraine: Therapy with Combined Peripheral Neurostimulation. <i>Headache</i> , 2015 , 75-80		
95	Impact of migraine on fibromyalgia symptoms. <i>Journal of Headache and Pain</i> , 2015 , 17, 28	8.8	51
94	Treatment of menstrual migraine: utility of control of related mood disturbances. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 493-502	4.3	7
93	Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1381-95	5.5	10
92	Framing comorbidities and co-occurrences in a migraine with aura patient. <i>Internal and Emergency Medicine</i> , 2014 , 9, 603-4	3.7	1
91	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1697-706	4	16
90	Pharmacogenetic insights into migraine treatment in children. <i>Pharmacogenomics</i> , 2014 , 15, 1539-50	2.6	12
89	Gleaning after the European Headache Federation consensus statement on refractory chronic migraine. <i>Journal of Headache and Pain</i> , 2014 , 15, 75	8.8	
88	Journal Citation Reports [®] 2013 tells headache experts that competitive environment has changed. <i>Journal of Headache and Pain</i> , 2014 , 15,	8.8	78
87	Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2014 , 15, 79	8.8	69
86	Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2014 , 15, 47	8.8	72
85	Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. <i>Journal of Headache and Pain</i> , 2013 , 14, 87	8.8	23
84	A six year retrospective review of occipital nerve stimulation practice--controversies and challenges of an emerging technique for treating refractory headache syndromes. <i>Journal of Headache and Pain</i> , 2013 , 14, 67	8.8	60
83	The omics in migraine. <i>Journal of Headache and Pain</i> , 2013 , 14, 55	8.8	15
82	Pharmacokinetic evaluation of almotriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 637-44	5.5	6
81	Overattachment and perceived disability in chronic migraineurs. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 954-8	2	16
80	New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?. <i>Journal of Headache and Pain</i> , 2013 , 14, 9	8.8	46

79	Neuromodulation of chronic headaches: position statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2013 , 14, 86	8.8	141
78	Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1043-50	5.5	10
77	Ictal epileptic headache: an old story with courses and appeals. <i>Journal of Headache and Pain</i> , 2012 , 13, 607-13	8.8	38
76	White matter hyperintensities and self-reported depression in a sample of patients with chronic headache. <i>Journal of Headache and Pain</i> , 2012 , 13, 661-7	8.8	13
75	Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2369-80	4	19
74	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 393-406	3.7	51
73	Treatment of perimenstrual migraine with triptans: an update. <i>Current Pain and Headache Reports</i> , 2012 , 16, 445-51	4.2	15
72	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. <i>Journal of Headache and Pain</i> , 2012 , 13, 401-6	8.8	20
71	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). <i>Journal of Headache and Pain</i> , 2012 , 13, 361-78	8.8	198
70	'Ictal epileptic headache': recent concepts for new classifications criteria. <i>Cephalalgia</i> , 2012 , 32, 723-4	6.1	64
69	CGRP receptor antagonists: an expanding drug class for acute migraine?. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 807-18	5.9	53
68	Deciphering the task of N-acetyl aspartate in migraine. <i>Expert Review of Neurotherapeutics</i> , 2012 , 12, 1057-9	4.3	5
67	Pharmacokinetic evaluation of frovatriptan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1449-58	5.5	14
66	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. <i>Journal of Headache and Pain</i> , 2011 , 12, 361-8	8.8	41
65	Chronic migraine plus medication overuse headache: two entities or not?. <i>Journal of Headache and Pain</i> , 2011 , 12, 593-601	8.8	68
64	Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?. <i>Internal and Emergency Medicine</i> , 2011 , 6, 23-8	3.7	11
63	Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 39-47	5.5	15
62	Lifting The Burden: The Global Campaign Against Headache 2011 , 737-744		3

61	Medical Interventions for Migraine That Has Become Difficult to Treat 2011 , 423-434		
60	Treatment and Prevention of Migraine 2011 , 255-263		
59	Chronic migraine: current concepts and ongoing treatments. <i>European Review for Medical and Pharmacological Sciences</i> , 2011 , 15, 1401-20	2.9	21
58	Psychiatric comorbidity and suicide risk in patients with chronic migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 81-91	3.1	62
57	Patient outcome in migraine prophylaxis: the role of psychopharmacological agents. <i>Patient Related Outcome Measures</i> , 2010 , 1, 107-18	2.9	11
56	Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. <i>Journal of Headache and Pain</i> , 2010 , 11, 151-6	8.8	25
55	Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. <i>Journal of Headache and Pain</i> , 2010 , 11, 431-5	8.8	30
54	Chronic migraine: comorbidities, risk factors, and rehabilitation. <i>Internal and Emergency Medicine</i> , 2010 , 5 Suppl 1, S13-9	3.7	75
53	The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers. <i>Journal of Headache and Pain</i> , 2009 , 10, 21-6	8.8	15
52	Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. <i>Journal of Headache and Pain</i> , 2009 , 10, 283-90	8.8	109
51	Future drugs for migraine. <i>Internal and Emergency Medicine</i> , 2009 , 4, 367-73	3.7	19
50	Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. <i>Cephalalgia</i> , 2009 , 29, 1285-93	6.1	82
49	Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1347-54	4.3	13
48	Headache and emergency medicine: sharing a language for a common project. <i>Internal and Emergency Medicine</i> , 2008 , 3 Suppl 1, S1-2	3.7	1
47	Acute migraine in the Emergency Department: extending European principles of management. <i>Internal and Emergency Medicine</i> , 2008 , 3 Suppl 1, S17-24	3.7	12
46	Thoughts on the past year of Journal of Headache and Pain. <i>Journal of Headache and Pain</i> , 2008 , 9, 1-2	8.8	0
45	Prevalence and burden of primary headache in Akaki textile mill workers, Ethiopia. <i>Journal of Headache and Pain</i> , 2008 , 9, 119-28	8.8	25
44	Improving care through health economics analyses: cost of illness and headache. <i>Journal of Headache and Pain</i> , 2008 , 9, 199-206	8.8	43

43	Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. <i>Journal of Headache and Pain</i> , 2008 , 9, 349-57	8.8	25
42	Role of NSAIDs in acute treatment of headache. <i>Drug Development Research</i> , 2007 , 68, 276-281	5.1	6
41	Headache medicine: academic teaching in Europe. The Sapienza University Master's Degree. <i>Headache</i> , 2007 , 47, 1224-5; author reply 1225-7	4.2	5
40	Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1256-69	2.9	22
39	Aspirin and tension-type headache. <i>Journal of Headache and Pain</i> , 2007 , 8, 49-55	8.8	14
38	Genetics of migraine and pharmacogenomics: some considerations. <i>Journal of Headache and Pain</i> , 2007 , 8, 334-9	8.8	33
37	Chronic daily headache and medication overuse headache: clinical read-outs and rehabilitation procedures. <i>Clinica Terapeutica</i> , 2007 , 158, 343-7		3
36	Aids for management of common headache disorders in primary care. <i>Journal of Headache and Pain</i> , 2007 , 8 Suppl 1, S2	8.8	9
35	Neuroendocrine derangement in chronic migraine. <i>Headache</i> , 2006 , 46, 1309-10	4.2	3
34	Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine. <i>Journal of Headache and Pain</i> , 2006 , 7, 90-4	8.8	38
33	The road ahead for chronic headache patients. <i>Journal of Headache and Pain</i> , 2006 , 7, 317-9	8.8	0
32	Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. <i>Journal of Headache and Pain</i> , 2006 , 7, 407-12	8.8	30
31	Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migraine. <i>Journal of Headache and Pain</i> , 2005 , 6, 188-90	8.8	2
30	Headache and mood disorders. <i>Journal of Headache and Pain</i> , 2005 , 6, 250-3	8.8	7
29	The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). <i>Journal of Headache and Pain</i> , 2005 , 6, 261-3	8.8	19
28	A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache. <i>Journal of Headache and Pain</i> , 2004 , 5, 188-191	8.8	3
27	Health status after detoxification in medication overuse headache. <i>Journal of Headache and Pain</i> , 2004 , 5, 215-216	8.8	0
26	Cervicogenic headache: practical approaches to therapy. <i>CNS Drugs</i> , 2004 , 18, 793-805	6.7	38

25	Reduction in expenditures on analgesics during one year of treatment of chronic tension headache with BoNT-A. <i>Journal of Headache and Pain</i> , 2003 , 4, 88-91	8.8	3
24	Analgesic therapy for headache: consumption, appropriateness and costs. <i>Journal of Headache and Pain</i> , 2003 , 4, s84-s87	8.8	1
23	Inflammatory mechanisms in cervicogenic headache: an integrative view. <i>Current Pain and Headache Reports</i> , 2002 , 6, 315-9	4.2	8
22	Tumor necrosis factor gene polymorphism in migraine. <i>Headache</i> , 2002 , 42, 341-5	4.2	46
21	Nitric oxide: emerging implications for headache mechanics. <i>Journal of Headache and Pain</i> , 2001 , 2, 67-73	3.8	4
20	Proinflammatory pathways in cervicogenic headache. <i>Clinical and Experimental Rheumatology</i> , 2000 , 18, S33-8	2.2	19
19	Chromosome 6p-encoded HLA-DR2 determination discriminates migraine without aura from migraine with aura. <i>Human Immunology</i> , 1999 , 60, 69-74	2.3	22
18	Proinflammatory cytokines in cervicogenic headache. <i>Functional Neurology</i> , 1999 , 14, 159-62	2.2	14
17	Modulation of nitric oxide synthase by nitric oxide donor compounds in migraine. <i>International Journal of Clinical and Laboratory Research</i> , 1998 , 28, 135-9		22
16	Epidural steroid-based technique for cervicogenic headache diagnosis. <i>Functional Neurology</i> , 1998 , 13, 84-7	2.2	3
15	Failure of long-term results of epidural steroid injection in cervicogenic headache. <i>European Review for Medical and Pharmacological Sciences</i> , 1998 , 2, 10	2.9	6
14	Epidural corticosteroid blockade in cervicogenic headache. <i>European Review for Medical and Pharmacological Sciences</i> , 1998 , 2, 31-6	2.9	14
13	Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients. <i>Journal of Molecular Medicine</i> , 1997 , 75, 448-53	5.5	34
12	Hyperbaric oxygen in chronic cluster headaches: influence on serotonergic pathways. <i>Undersea and Hyperbaric Medicine</i> , 1997 , 24, 117-22	0.9	19
11	Putative neuroimmunological mechanisms in cluster headache. An integrated hypothesis. <i>Headache</i> , 1996 , 36, 312-5	4.2	20
10	"Capsaicin-sensitive" sensory neurons in cluster headache: pathophysiological aspects and therapeutic indication. <i>Headache</i> , 1994 , 34, 132-7	4.2	21
9	Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan. <i>International Journal of Clinical Pharmacology Research</i> , 1994 , 14, 165-75		4
8	IL-2 Induces Pha Proliferation in Peripheral Blood Mononuclear Cells from Cluster Headache Patients. <i>Cephalalgia</i> , 1991 , 11, 270-271	6.1	1

7	Bioelectrical impedance assay (BIA) of total body composition in alcohol-induced migraine patients. Preliminary report. <i>Headache</i> , 1991 , 31, 41-5	4.2	1
6	Evidence for an immune-mediated mechanism in food-induced migraine from a study on activated T-cells, IgG4 subclass, anti-IgG antibodies and circulating immune complexes. <i>Headache</i> , 1989 , 29, 664-70	4.2	13
5	Reduced IL-2 Receptor Expression on Peripheral Blood Lymphocytes from Cluster Headache Patients. <i>Cephalalgia</i> , 1989 , 9, 162-163	6.1	
4	Immune Response Time-Course after Challenge Test in Food-Induced Migraine. <i>Cephalalgia</i> , 1989 , 9, 164-165	6.1	1
3	Progressive Deactivation of 5HT Receptors on Mononuclear Cells during Migraine Crisis. <i>Cephalalgia</i> , 1989 , 9, 93-94	6.1	15
2	In vitro interactions of serotonin (5-HT) with mononuclear cells from migraine patients: alterations related to the phase of the attack. <i>Journal of Neuroimmunology</i> , 1988 , 18, 17-24	3.5	7
1	Raised Titers Of Antibodies To Herpes And Epstein-Barr Viruses In Cluster Headache Detected By Immunofluorescence. <i>Cephalalgia</i> , 1987 , 7, 351-352	6.1	3